-
Signature
-
/s/ Mardi Dier, as Attorney-in-Fact
-
Stock symbol
-
MDGL
-
Transactions as of
-
Aug 11, 2025
-
Transactions value $
-
-$16,069,956
-
Form type
-
4
-
Date filed
-
8/13/2025, 05:33 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Taub Rebecca |
Director |
C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN |
/s/ Mardi Dier, as Attorney-in-Fact |
2025-08-13 |
0001423898 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
MDGL |
Common Stock |
Options Exercise |
$30.2K |
+3.2K |
+0.69% |
$9.45 |
464K |
Aug 11, 2025 |
Direct |
|
| transaction |
MDGL |
Common Stock |
Sale |
-$1.04M |
-2.98K |
-0.64% |
$350.18 |
461K |
Aug 11, 2025 |
Direct |
F1, F2 |
| transaction |
MDGL |
Common Stock |
Sale |
-$77.2K |
-220 |
-0.05% |
$351.02 |
461K |
Aug 11, 2025 |
Direct |
F1, F3 |
| transaction |
MDGL |
Common Stock |
Options Exercise |
$409K |
+43.3K |
+9.38% |
$9.45 |
504K |
Aug 12, 2025 |
Direct |
|
| transaction |
MDGL |
Common Stock |
Sale |
-$1.26M |
-3.58K |
-0.71% |
$350.87 |
501K |
Aug 12, 2025 |
Direct |
F1, F4 |
| transaction |
MDGL |
Common Stock |
Sale |
-$1.01M |
-2.87K |
-0.57% |
$351.60 |
498K |
Aug 12, 2025 |
Direct |
F1, F5 |
| transaction |
MDGL |
Common Stock |
Sale |
-$414K |
-1.18K |
-0.24% |
$352.45 |
497K |
Aug 12, 2025 |
Direct |
F1, F6 |
| transaction |
MDGL |
Common Stock |
Sale |
-$1.62M |
-4.59K |
-0.92% |
$354.04 |
492K |
Aug 12, 2025 |
Direct |
F1, F7 |
| transaction |
MDGL |
Common Stock |
Sale |
-$2.3M |
-6.48K |
-1.32% |
$354.97 |
486K |
Aug 12, 2025 |
Direct |
F1, F8 |
| transaction |
MDGL |
Common Stock |
Sale |
-$2.05M |
-5.75K |
-1.18% |
$355.95 |
480K |
Aug 12, 2025 |
Direct |
F1, F9 |
| transaction |
MDGL |
Common Stock |
Sale |
-$1.74M |
-4.86K |
-1.01% |
$356.88 |
475K |
Aug 12, 2025 |
Direct |
F1, F10 |
| transaction |
MDGL |
Common Stock |
Sale |
-$2.4M |
-6.72K |
-1.41% |
$357.85 |
468K |
Aug 12, 2025 |
Direct |
F1, F11 |
| transaction |
MDGL |
Common Stock |
Sale |
-$2.35M |
-6.54K |
-1.4% |
$358.81 |
462K |
Aug 12, 2025 |
Direct |
F1, F12 |
| transaction |
MDGL |
Common Stock |
Sale |
-$252K |
-700 |
-0.15% |
$359.71 |
461K |
Aug 12, 2025 |
Direct |
F1, F13 |
| holding |
MDGL |
Common Stock |
|
|
|
|
|
656K |
Aug 11, 2025 |
By SQN LLC |
F14 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
MDGL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3.2K |
-6.89% |
$0.00 |
43.3K |
Aug 11, 2025 |
Common Stock |
3.2K |
$9.45 |
Direct |
F15 |
| transaction |
MDGL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-43.3K |
-100% |
$0.00 |
0 |
Aug 12, 2025 |
Common Stock |
43.3K |
$9.45 |
Direct |
F15 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: